Novavax, Inc.
NVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.03 | -0.00 | 0.12 |
| FCF Yield | 7.52% | -12.51% | -18.09% | -13.62% |
| EV / EBITDA | -7.81 | 8.17 | 1.87 | -18.48 |
| Quality | ||||
| ROIC | -23.50% | 10.93% | 58.69% | -34.95% |
| Gross Margin | 69.49% | 94.05% | 97.88% | 58.48% |
| Cash Conversion Ratio | -0.53 | -1.20 | -0.36 | 2.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.51% | -9.19% | 1.45% | -27.81% |
| Free Cash Flow Growth | 182.83% | 31.60% | -6.45% | -20.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | -0.30 | -0.06 | 5.61 |
| Interest Coverage | 32.47 | 19.15 | 90.08 | -17.28 |
| Efficiency | ||||
| Inventory Turnover | 1.59 | 1.39 | 1.38 | 4.19 |
| Cash Conversion Cycle | 36.48 | -170.15 | -146.38 | 29.78 |